NasdaqGM - Delayed Quote USD

Alvotech (ALVO)

Compare
12.41
-0.16
(-1.27%)
At close: January 30 at 4:00:01 PM EST
12.41
0.00
(0.00%)
After hours: January 30 at 4:00:12 PM EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ALVO

Recent News: ALVO

View More
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
GlobeNewswire 3 days ago
Alvotech's (NASDAQ:ALVO) largest shareholders are private equity firms with 34% ownership, private companies own 31%

Alvotech's (NASDAQ:ALVO) largest shareholders are private equity firms with 34% ownership, private companies own 31%
Simply Wall St. 4 days ago
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
GlobeNewswire last month
Exploring Three High Growth Tech Stocks in the United States

Exploring Three High Growth Tech Stocks in the United States
Simply Wall St. last month
Alvotech Third Quarter 2024 Earnings: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023)

Alvotech Third Quarter 2024 Earnings: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023)
Simply Wall St. 2 months ago

Alvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements
GuruFocus.com 2 months ago
Alvotech Reports Financial Results for the First Nine Months of 2024

Alvotech Reports Financial Results for the First Nine Months of 2024
GlobeNewswire 2 months ago
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
GlobeNewswire 2 months ago
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
GlobeNewswire 2 months ago
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
GlobeNewswire 2 months ago
Exploring High Growth Tech Stocks In The US October 2024

Exploring High Growth Tech Stocks In The US October 2024
Simply Wall St. 3 months ago
View More

Related Tickers

TEVA.TA Teva Pharmaceutical Industries Limited
6,400.00
-5.67%
 
ALM.MC Almirall, S.A.
9.51
+0.58%
 
KMDA Kamada Ltd.
6.71
-0.45%
 
AMRX Amneal Pharmaceuticals, Inc.
8.58
-1.72%
 
ELAN Elanco Animal Health Incorporated
12.47
+1.46%
 
HLUN-B.CO H. Lundbeck A/S
43.24
+0.98%
 
EVOTF Evotec SE
8.27
0.00%
 
AX9.SG Akebia Therapeutics Inc
2.2000
+0.73%
 
6CQ.BE Cresco Labs Inc
0.8860
+5.29%
 
CASBF CanSino Biologics Inc.
3.3740
0.00%